The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II safety and preliminary efficacy of amulirafusp alfa (IMM0306) in combination with lenalidomide in patients with relapsed or refractory CD20-positive follicular lymphoma.
 
Yan Huang
No Relationships to Disclose
 
Yanyan Liu
No Relationships to Disclose
 
Hongming He
No Relationships to Disclose
 
Ou Bai
No Relationships to Disclose
 
Zhiming Li
No Relationships to Disclose
 
Caixia Li
No Relationships to Disclose
 
Xingli Zhao
No Relationships to Disclose
 
Xiaobo Wang
No Relationships to Disclose
 
Ningjing Lin
No Relationships to Disclose
 
Lijuan Deng
No Relationships to Disclose
 
Zhihua Yao
No Relationships to Disclose
 
Jiuyang Zhang
No Relationships to Disclose
 
Ying Chen
No Relationships to Disclose
 
Wei Meng
No Relationships to Disclose
 
Qiying Lu
Leadership - ImmuneOnco Biopharmaceuticals
 
Wenzhi Tian
Leadership - ImmuneOnco Biopharmaceuticals
Stock and Other Ownership Interests - ImmuneOnco Biopharmaceuticals
 
Yuqin Song
No Relationships to Disclose